{
  "docId": "019de073-7087-77cd-a846-97dda09bac98",
  "docSlug": "031593eaf739f40f0f0c49214c912ed3",
  "documentTitle": "9 Meters Biopharma | Investor Presentation Deck | 30 slides",
  "authorId": "9-meters-biopharma",
  "authorName": "9 Meters Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 29,
  "pageCount": 30,
  "prevPage": 28,
  "nextPage": 30,
  "slideType": "timeline",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-7087-77cd-a846-97dda09bac98/29",
  "deckHref": "/decks/019de073-7087-77cd-a846-97dda09bac98",
  "deckJsonHref": "/decks/019de073-7087-77cd-a846-97dda09bac98.json",
  "deckAnchorHref": "/decks/019de073-7087-77cd-a846-97dda09bac98#slide-29",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.87,
        "x": 0.065,
        "y": 0.23
      },
      "kind": "diagram",
      "text": "2022 timeline with 1H22 and 2H22 markers",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b36f93aa-4dbf-46a2-ac08-f717b50bd2ea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.18,
        "y": 0.42
      },
      "kind": "list",
      "text": "1H22: Vurolenatide (SBS) Phase 2 trial preliminary results; Larazotide (celiac) Phase 3 trial interim analysis",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4d9b074c-b076-4f39-8eb7-23dcb58d6f4d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.35,
        "x": 0.55,
        "y": 0.42
      },
      "kind": "list",
      "text": "2H22: Vurolenatide (SBS) end-of-Phase 2 meeting with FDA; Vurolenatide (SBS) Phase 2 final results; Vurolenatide (SBS) Phase 3 protocol finalization; Vurolenatide (SBS) Phase 3 trial initiation; NM-102 progression toward IND; NM-136 progression toward IND",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "57f5c6cf-0d4e-41aa-946f-04b14320e44f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.35,
        "x": 0.076,
        "y": 0.135
      },
      "kind": "title",
      "text": "Near-term development milestones",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9e1f4676-c772-425f-9e17-4de820054c67",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "8683fc16-175b-465a-b6c9-6569dd7982df",
      "evidence": "Visual representation of events over a 2022 time horizon",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 29,
      "from": 28,
      "beatId": "7d443e0f-6581-415b-afc6-e5fd8a41939e",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Next Steps",
      "beatSlug": null,
      "evidence": "Slides 28-29 outline next steps",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}